enGene (NASDAQ:ENGN) Receives Market Perform Rating from Citizens Jmp

Key Points

• Citizens Jmp reaffirmed a “market perform” rating on enGene, while the broader analyst consensus remains “Hold” with a $11.05 average price target.
• enGene shares rose 5.5% to $1.92, but remain well below their 52-week high of $12.25; the stock’s market capitalization is approximately $128.6 million.
• The clinical-stage biotechnology company missed quarterly earnings expectations, reporting a loss of $0.47 per share versus the estimated $0.43 loss. Institutional investors own 64.16% of the company.

enGene (NASDAQ:ENGN - Get Free Report)'s stock had its "market perform" rating reaffirmed by equities research analysts at Citizens Jmp in a research note issued to investors on Wednesday, Benzinga reports.

A number of other research firms have also commented on ENGN. UBS Group lowered their price target on enGene from $9.00 to $2.00 and set a "neutral" rating for the company in a research report on Thursday, May 14th. Wall Street Zen upgraded enGene from a "strong sell" rating to a "sell" rating in a research report on Saturday, August 15th. Citigroup reissued a "market perform" rating on shares of enGene in a research note on Wednesday. Weiss Ratings restated a "sell (e+)" rating on shares of enGene in a report on Wednesday, August 12th. Finally, HC Wainwright reaffirmed a "buy" rating and issued a $4.00 price target on shares of enGene in a research note on Tuesday. Four research analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and two have issued a Sell rating to the company. According to MarketBeat, the stock currently has a consensus rating of "Hold" and a consensus target price of $11.05.

enGene Trading Up 5.5%

NASDAQ:ENGN opened at $1.92 on Wednesday. The company has a fifty day moving average of $1.82 and a 200 day moving average of $4.05. enGene has a 52 week low of $1.40 and a 52 week high of $12.25. The company has a quick ratio of 12.57, a current ratio of 12.57 and a debt-to-equity ratio of 0.10. The firm has a market capitalization of $128.62 million, a P/E ratio of -0.88 and a beta of -0.28.

enGene (NASDAQ:ENGN - Get Free Report) last announced its quarterly earnings results on Tuesday, September 8th. The company reported ($0.47) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.43) by ($0.04). On average, research analysts predict that enGene will post -1.75 earnings per share for the current year.

Hedge Funds Weigh In On enGene

A number of hedge funds have recently bought and sold shares of ENGN. Cresset Asset Management LLC bought a new stake in enGene during the 2nd quarter valued at about $36,000. Raymond James Financial Inc. raised its holdings in enGene by 383.6% in the 3rd quarter. Raymond James Financial Inc. now owns 10,000 shares of the company's stock worth $68,000 after acquiring an additional 7,932 shares during the last quarter. Paloma Partners Management Co purchased a new position in enGene in the 2nd quarter worth approximately $38,000. Jump Financial LLC bought a new position in enGene in the 4th quarter valued at approximately $121,000. Finally, Millennium Management LLC lifted its position in enGene by 57.3% in the 3rd quarter. Millennium Management LLC now owns 20,502 shares of the company's stock valued at $140,000 after acquiring an additional 7,472 shares in the last quarter. Institutional investors own 64.16% of the company's stock.

About enGene

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.